Close
CDMO Safety Testing 2026
Novotech

Elligo Health Research Launches Novel IntElligo Research Stack Clinical Technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.
- Advertisement -

Elligo Health Research, an integrated research organization (IRO), announces the launch of its innovative IntElligo Research Stack™ clinical technology.

This standards-based technology platform, which powers the System of Accelerated Research (SOAR™) model, will be launched this month as the eSource documentation tool at Elligo’s Research Ready network of study sites.

 ”IntElligo can be set up per the study protocol in hours and easily follows the workflow in any physician’s office,” said Jacylyn Bodmer, Elligo’s chief information officer. “We are improving data quality while relieving administrative burden at the research site and enabling more patient-centric interactions. IntElligo also facilitates remote monitoring, which results in faster source data verification and financial payments to our physicians.”                                                                                                                                  

“IntElligo bridges health care and research, leveraging global industry standards from the start (CDISC PRM and CDASH), thus facilitating aggregation and tabulation into CDISC SDTM, the required format for regulatory eSubmissions to the FDA and Japan’s PMDA,” added Rebecca Kush, Ph.D., Elligo’s chief scientific officer.

In addition, the technology provides real-time management financial management, reports, and analytics across research sites; saves time and preserves data integrity by eliminating transcription; and, achieves true eSource. Furthermore, it creates the opportunity to transform research through the SOAR™ model — expanding patient access and driving efficiency by enabling direct data from source to submission.  

“By uniting our Goes Direct® approach with this technology and infrastructure to support physicians, we are creating the ultimate solution for clinical trial execution,” said John Potthoff, Ph.D., Elligo CEO. “The IntElligo platform will become a primary resource for our study sites, increasing the ability for physicians to provide research as a care option and enabling more patients to benefit.” 

About Elligo
Elligo Health Research, an integrated research organization, accelerates the development of new pharmaceutical, biotechnology, medical device, and diagnostic products using our novel IntElligo Research Stack™ clinical technology and our Goes Direct® approach. We unite the best clinical experts with the best research infrastructure — creating the ultimate clinical trial solution. By maintaining the integrity of the trusted patient and physician relationship and building global communities of research that leverage electronic health records, we ensure all patients have access to clinical trials as a care option. Learn more at elligodirect.com

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

Early Phase Decisions Drive Faster Drug Development

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »